Optimal Timing of Intrauterine Insemination (IUI) When Utilizing Superovulation Combined With GnRH Antagonists

A Randomized Open Three Arm Prospective Trial To Determine The Optimal Timing for Intrauterine Insemination After Superovulation With Recombinant Gonadotropins Utilizing GnRH Antagonists

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00675142

Enrollment

107

Registered

2008-05-08

Start date

2008-05-31

Completion date

2011-08-31

Last updated

2015-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Infertility, Intra-uterine insemination, ovarian stimulation

Brief summary

The timing of IUI following ovulation induction has been the subject of many studies and a consensus has developed that a single insemination approximately thirty-six hours after ovulation induction is sufficien. The introduction of GnRH antagonists preventing a premature LH surge and early ovulation has added a new dimension to fertility treatment. It allows greater accuracy in predicting the timing of ovulation and has been shown to be at least as effective, if not more effective, as ovarian stimulation without antagonists. We hypothesize that by utilizing GnRH antagonists we can increase pregnancy rates during IUI by timing the IUI as close as possible to the moment of ovulation guaranteeing the highest and freshest concentration of motile spermatozoa in the fallopian tube at the time the oocyte is released from the ovary. We therefore propose a randomized open three arm prospective trial utilizing superovulation with GnRH antagonists whereby the IUI is timed to take place 36, 42 or 48 hours after ovulation induction.

Interventions

PROCEDUREIntrauterine Insemination

Changing the time span between ovulation induction and IUI during fertility treatment.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Women with infertility who are candidates for controlled ovarian stimulation and intrauterine insemination with * Ovulatory disorder * male factor * partial mechanical factor * endometriosis * unexplained infertility.

Exclusion criteria

* Known allergy to one or more of the utilized drugs * Neither fallopian tube is patent * Sperm count less than 1 million total motile sperm of normal morphology during at least two investigations * Women who are candidates for mono-ovulation. * failure to receive consent * women with baseline functional cysts (i.e. hormone producing) above 12 mm diameter.

Design outcomes

Primary

Measure	Time frame
Achieving pregnancy	2 weeks after intervention

Secondary

Measure	Time frame
Live Birth	9 months after interventio

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026